http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022202895-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1870024223df71c715c62d0edd723acb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d77148b200d14a99fec87084a6c9c2a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
| filingDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47b818cb49ba0f3d5afc430a137febff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6bea11dbc5fd0ec9a5c7988cdac2e40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa5bd47bdfe7698d525b44373b4f4953 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f002feb8684ab19f7fd1a46456acdf3c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec6b0a978ec0d46523f49c9c61ab0b6a |
| publicationDate | 2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022202895-A1 |
| titleOfInvention | Pulsative gnrh administration for treating cognitive disorders |
| abstract | The present invention pertains to novel therapeutic ways for treating cognitive disorders associated with olfactory dysfunction. By using a mouse model of Down syndrome (DS—Ts65Dn mice), the present inventors have demonstrated that GnRH insufficiency is involved in the age-dependent acquisition of cognitive decline in DS and that pulsatile GnRH treatment allows reversing olfactory- and cognitive-associated impairments in DS. The present inventors have further demonstrated that GnRH insufficiency is involved in the pathological pathways of cognitive disorders in which the cognitive decline is associated with olfactory dysfunction, and, accordingly, that pulsatile GnRH administration can be used for the treatment of cognitive disorders associated with olfactory dysfunction. Accordingly, the present invention pertains to the use of GnRH for the treatment of cognitive disorders, said GnRH being administered by pulsatile administration. The present invention further pertains to a miR-200 and/or a miR-155, which are known to be involved in GnRH-secretion regulation, for use in the treatment of cognitive disorders. |
| priorityDate | 2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 341.